Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06864026
- Locations
- 🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler, Chandler, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff, Arizona, United States
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT06859294
- Locations
- 🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa, Mesa, Arizona, United States
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 643
- Registration Number
- NCT06859268
- Locations
- 🇺🇸
Southern California Clinical Research, Santa Ana, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸CMR of Greater New Haven, LLC, Hamden, Connecticut, United States
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06857942
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸First OC Dermatology Research Inc, Fountain Valley, California, United States
🇺🇸Northridge Clinical Trials, Northridge, California, United States
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT06824051
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Axis, Dilworth, Minnesota, United States
🇺🇸Ohio Clinical Trials, Columbus, Ohio, United States
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06817356
- Locations
- 🇺🇸
Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Woodland Resarch Northwest/ERG, Rogers, Arkansas, United States
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 127
- Registration Number
- NCT06809400
- Locations
- 🇺🇸
K2 Medical Research, LLC, Maitland, Florida, United States
🇺🇸Aqualane Clinical Research, Naples, Florida, United States
🇺🇸Charter Research, The Villages, Florida, United States
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06808802
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06739122
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States
A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-23
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly & Co.
- Target Recruit Count
- 13
- Registration Number
- 2024-518502-40-00
- Locations
- 🇩🇰
Odense University Hospital, Odense C, Denmark
🇫🇷Centre Hospitalier Universitaire De Dijon, Dijon, France
🇫🇷Centre Hospitalier Universitaire De Bordeaux, Pessac, France